T1	PrimaryOutcome 39 66	reduction of viral RNA load
T2	TimeFrame 91 128	at days 3 and 7 after treatment start
R1	MeasuredAt Arg1:T1 Arg2:T2	
T3	SecondaryOutcome 158 178	clinical progression
T4	SecondaryOutcome 445 503	time from randomization to complete resolution of symptoms
T5	TimeFrame 504 538	within the 28-day follow-up period
R2	MeasuredAt Arg1:T4 Arg2:T5	
T6	OutcomeDefinition 540 698	Resolution of symptoms was assessed sequentially using a symptoms questionnaire designed to gather information on the type of symptom and last day experienced
R3	DefinedAs Arg1:T4 Arg2:T6	
T7	OtherOutcome 816 850	AEs that occurred during treatment
T8	OtherOutcome 852 856	SAEs
T9	OtherOutcome 858 895	AEs of special interest (ie, cardiac)
T10	OtherOutcome 901 937	premature discontinuation of therapy
T11	OutcomeDefinition 948 1048	classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events
R4	DefinedAs Arg1:T7 Arg2:T11	
T12	OutcomeDefinition 222 243	WHO progression scale
R5	DefinedAs Arg1:T3 Arg2:T12	
